| Date | Title | Description |
| 18.06.2025 | The Dawn of Radioligand Therapies: A New Era in Precision Oncology | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ... |
| 16.06.2025 | Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology | New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth
LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global ... |
| 13.06.2025 | The Rise of Canadian Life Sciences: A New Era of Innovation and Investment | In the heart of Canada, a revolution is brewing. The life sciences sector is experiencing a surge, fueled by innovative companies and strategic investments. Two recent announcements highlight this trend: Genesys Capital's closing of its lar... |
| 11.06.2025 | Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP | TORONTO & MONTREAL–(BUSINESS WIRE)–June 11, 2025–
Genesys Capital (“Genesys”) is pleased to announce the upcoming closing of Genesys Ventures IV LP (“Fund IV” or the “fund”) to continue its successful track record of building Canadian l... |
| 25.04.2024 | 1st Quarter Results | 1st Quarter Results
Thu, Apr 25, 2024 08:00 CET Report this content
AstraZeneca
25 April 2024
Q1 2024 results
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Revenue and EPS summary
Q1 2024 % ... |
| 25.03.2024 | AstraZeneca to Acquire Fusion Pharmaceuticals, for Up To $2.4 Billion | AstraZeneca (LSE/STO/Nasdaq: AZN) has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a Hamilton, Canada-based clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
Under the ... |
| 21.03.2024 | AstraZeneca Acquires Fusion Pharmaceuticals for $2B to Bolster Radioconjugate Pipeline | What You Should Know:
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
The acquisition marks a major ste... |
| 19.03.2024 | AstraZeneca to acquire Fusion | AstraZeneca to acquire Fusion
Tue, Mar 19, 2024 08:00 CET Report this content
19 March 2024
AstraZeneca to acquire Fusion to accelerate the development of
next-generation radioconjugates to treat cancer
Includes actinium-based clinical-stag... |
| 19.03.2024 | Astrazeneca expands cancer treatment stable with purchase of Canada-based Fusion | Pharmaceutical giant Astrazeneca is expanding its cancer treatment capabilities through the acquisition of a major oncology group.
London-listed Astrazeneca today said it would pay $2bn (£1.5bn) cash up front for Canada-based Fusion Pharmac... |
| 19.03.2024 | AstraZeneca Joins Radiopharma Deals Spree With $2B Fusion Acquisition | AstraZeneca is following in the footsteps of some of its big pharmaceutical company peers, plunking down $2 billion to acquire its radiopharmaceuticals partner Fusion Pharmaceuticals. More than adding a pipeline of targeted radiation therap... |
| 03.05.2023 | Fusion Pharmaceuticals Announces Opening Of Radiopharmaceutical Manufacturing Facility To Produce Targeted Alpha Therapies For Cancer | HAMILTON, ON, May 2, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the opening of its sta... |
| 21.04.2023 | Fusion Pharmaceuticals Announces Presentation Of Preclinical Data Supporting FPI-2059 And Leading Targeted Alpha Therapy Platform At AACR Annual Meeting | FPI-2059 induces tumor growth inhibition in colorectal tumor model
TEM-1 and EGFRvIII demonstrate potential as TAT targets
HAMILTON, ON and BOSTON, April 19, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage... |
| 14.04.2023 | Fusion Pharmaceuticals Announces IND Clearance For FPI-2068, A Jointly Developed Novel Targeted Alpha Therapy | FPI-2068 is a Bispecific Targeted Alpha Therapy (TAT) designed to Precisely Deliver Radiation to Tumor Cells
HAMILTON, ON and BOSTON, April 12, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology compa... |
| 12.04.2023 | Fusion Pharmaceuticals Announces IND Clearance For FPI-2068, A Jointly Developed Novel Targeted Alpha Therapy | Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the clearance of investigational new drug (IND) applications fo... |
| 22.03.2023 | Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1 Study Of FPI-2059, A Targeted Alpha Therapy (TAT) For The Treatment Of Solid Tumors Expressing NTSR1 | HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the... |
| 16.03.2023 | Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results And Clinical Program Updates | Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC
FPI-1434 preliminary Phase 1 data expected in Q2 2023
FPI-1966 and FPI-2059... |
| 15.02.2023 | Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer. | Hamilton, ON, Canada and Boston, MA, USA. 13 February 2023. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) (“Fusion”), a clinical-stage oncology company focused on developing next-generation targeted alpha therapies (“TATs”) as precision medici... |
| 07.01.2023 | Fusion Pharmaceuticals And BWXT Medical Announce Actinium-225 Partnership To Scale Supply For Developing Targeted Alpha Therapies | – Agreement augments Fusion’s existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows
– Furthers BWXT Medical’s position as a global leader in medical isotope supply
HAMILTON, ON, Jan. 5, 2023 /PRNe... |
| 09.11.2022 | Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results And Clinical Program Updates | FPI-1434 Phase 1 data on track to be reported in first half of 2023
Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3
Strong balance sheet with $205.5 million in cash, cash equivalents and investme... |
| 08.11.2022 | Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. As Chief Medical Officer | Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical offic... |
| 30.08.2022 | Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3 | HAMILTON, ON and BOSTON, Aug. 29, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the ... |
| 11.08.2022 | Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results And Clinical Program Updates | FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy
Data supporting ongoing evaluation of cold antibody pre-administration dosing regimen in Phase 1 study of FPI-1434 presented at... |
| 22.06.2022 | Fusion Pharmaceuticals Presents Imaging Data From Cold Antibody Sub-Study In The Phase 1 Study Of FPI-1434 | Hamilton, Ontario, Canada and Boston, USA. 14 June 2022. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pr... |
| 09.02.2022 | Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | HAMILTON, ON and BOSTON, Feb. 9, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the ... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Presentation Of Preclinical Data Supporting Its FPI-1966 And FPI-2059 Targeted Alpha Therapies | Single and multiple doses of FPI-1966 demonstrated therapeutic efficacy in a preclinical bladder xenograft model
[225Ac]-FPI-2059 demonstrated superior efficacy against [177Lu]-IPN-1087 in a head-to-head comparison in a mouse xenograft mod... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Clinical Collaboration With Merck To Evaluate Fusion’s Targeted Alpha Therapy (TAT) In Combination With Merck’s KEYTRUDA® (Pembrolizumab) In Patients With Solid Tumors... | HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434 | Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity
Imaging shows drug uptake across multiple tumor types
E... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results And Business Update | Phase 1 study of FPI-1434 progressing towards multi-dose data and recommended Phase 2 dose in 1H2022
FPI-1966 advancing to clinic
HAMILTON, ON and BOSTON, Aug. 10, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical... |
| 12.01.2022 | Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. As Senior Vice President, Research | HAMILTON, ON and BOSTON, June 7, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appoin... |
| 12.01.2022 | Fusion Pharmaceuticals Enters Into Agreement To Build Radiopharmaceutical Manufacturing Facility | HAMILTON, ON and BOSTON, June 2, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered... |
| 12.01.2022 | Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results And Clinical Program Update | FPI-1434 Phase 1 multi-dose data now expected in 2H 2022
FPI-1966 Phase 1 study initiated; first patient expected to be dosed in Q1 2022
FPI-2059 investigational new drug application (IND) on track for first half 2022
HAMILTON, ON and BO... |
| 12.01.2022 | Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., As Chief Scientific Officer | – Eric Burak, Ph.D. Appointed as Chief Technology Officer
HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioph... |
| 12.01.2022 | Fusion Pharmaceuticals Appoints Mohit Rawat As President And Chief Business Officer | HAMILTON, ON and BOSTON, Sept. 28, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appo... |
| 12.01.2022 | Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing FGFR3 | HAMILTON, ON and BOSTON, July 28, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the ... |
| 12.01.2022 | Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results And Business Update | Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022
Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions
HAMILTON, ON and BOSTON, May 11, 2021 /PRNewswire/ — F... |
| 12.01.2022 | Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. As Senior Vice President, Business Development | HAMILTON, ON and BOSTON, Sept. 21, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appo... |
| 12.01.2022 | Fusion Pharmaceuticals And TRIUMF Announce Expanded R&D Collaboration For Actinium Supply Production | Fusion and TRIUMF to collaborate to produce actinium based on technology developed by TRIUMF
HAMILTON, ON and BOSTON and VANCOUVER, BC, Aug. 12, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology comp... |
| 09.11.2021 | Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update | FPI-1434 Phase 1 multi-dose data now expected in 2H 2022
FPI-1966 Phase 1 study initiated; first patient expected to be dosed in Q1 2022
FPI-2059 investigational new drug application (IND) on track for first half 2022
HAMILTON, ON and BOSTO... |
| 31.08.2021 | Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 10.08.2021 | Fusion Pharmaceuticals : Announces Second Quarter 2021 Financial Results and Business Update | Phase 1 study of FPI-1434 progressing towards multi-dose data and recommended Phase 2 dose in 1H2022
FPI-1966 advancing to clinic
HAMILTON, ON and BOSTON, Aug. 10, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-... |
| 10.08.2021 | Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update | |
| 29.07.2021 | Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing FGFR3 | HAMILTON, ON and BOSTON, July 28, 2021 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and... |
| 28.07.2021 | Fusion Pharmaceuticals : Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3 | HAMILTON, ON and BOSTON, July 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the... |
| 28.07.2021 | Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3 | |
| 07.07.2021 | Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 14.06.2021 | FUSION PHARMACEUTICALS INC.
Fusion Pharmaceuticals : Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434 | Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity
Imaging shows drug uptake across multiple tumor types
Enr... |
| 14.06.2021 | Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434 | |
| 11.05.2021 | Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update | |
| 06.05.2021 | Fusion Pharmaceuticals, Lumira Portfolio Company, Announces Clinical Collaboration with Merck to Evaluate Fusion’s Targeted Alpha Therapy (TAT) in Combination with Merck’s KEYTRUDA® (Pembrolizumab) in... | HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has... |
| 06.05.2021 | Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors... | |
| 06.05.2021 | FUSION PHARMACEUTICALS INC.
Fusion Pharmaceuticals : Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab... | HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it ha... |
| 29.03.2021 | FUSION PHARMACEUTICALS INC.
Fusion Pharmaceuticals : Corporate Presentation March 2021 | Corporate Presentation
March 2021
Forward-Looking Statements and Legal Disclaimers
This presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These fo... |
| 25.03.2021 | FUSION PHARMACEUTICALS INC.
Fusion Pharmaceuticals : Announces Fourth Quarter 2020 Financial Results and Business Update | - FPI-1434 Phase 1 study is progressing
- Recent transactions and partnerships expand and diversify Fusion's pipeline of targeted alpha therapies in development to treat a broad array of tumor types
HAMILTON, ON and BOSTON, March 25, 2021 /... |
| 25.03.2021 | Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update | |
| 02.03.2021 | Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen | Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Solid Tumors |
| 10.02.2021 | Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada | Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people are unaware of Canadian role in this industry. However, se... |
| 10.11.2020 | Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
USA - English
USA - English
USA - English
France - Français
España - español
USA - English | |
| 02.11.2020 | Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies | |
| 13.01.2020 | Precision oncology startup Fusion Pharmaceuticals raises $26 million CAD | Biopharmaceutical precision oncology startup Fusion Pharmaceuticals has received a commitment of up to $26 million CAD ($20 million USD) from the Canada Pension Plan Investment Board (CPPIB).
Fusion Pharmaceuticals views targeted alpha ther... |
| 15.04.2019 | Hamilton biopharmaceutical raises $140 million CAD for cancer therapy tech | Hamilton-based biopharmaceutical company Fusion Pharmaceuticals has announced the completion of a $140 million CAD ($105 million USD) Series B round, to help develop its targeted radiotherapy cancer treatment.
“[Fusion’s] early stage clinic... |
| 04.04.2019 | What Happens When ‘Fake It Till You Make It’ Goes Too Far: Term Sheet for April 4, 2019 | SECOND ACT
If you read the book Bad Blood or watched the HBO documentary The Inventor, both of which detail the implosion of blood testing company Theranos, you might think that there’s no way ex-CEO Elizabeth Holmes makes a comeback.
Paid ... |
| 02.04.2019 | Fusion Pharmaceuticals Raises $105 Million in Oversubscribed Series B Financing | BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million S... |
| 02.04.2019 | Fusion Pharmaceuticals Raises $105 Million in Oversubscribed Series B Financing | BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million S... |
| 02.04.2019 | Fusion Pharmaceuticals Raises $105M in Series B Financing | Fusion Pharmaceuticals, a Hamilton, Ontario, Canada and Boston, MA-based clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, completed a $105m Series B financing.
The round was ... |
| 01.04.2019 | Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing | - |
| 23.02.2018 | Seeking greater gender diversity, Alnylam promotes four female leaders; Paul Hastings starts post-OncoMed career as CEO of stealthy Nkarta | Leila Jalinous
→ Consistent with a goal to foster gender diversity in its leadership ranks, Alnylam has promoted four female leaders to VP level. Kelly Bierly is now VP, commercial counsel, providing legal support ... |
| 26.09.2017 | Term Sheet — Tuesday, September 26 | FRESH FUNDING
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Before Sequoia partner Pat Grady committed to the investment, he asked Cancel about whether he was planning to exit ... |
| 25.09.2017 | Fusion Pharmaceuticals Secures Additional $21M; Closes $46M Series A financing | Fusion Pharmaceuticals, a Hamilton, Canada-based clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, completed a second closing of its Series A financing, securing an additional... |
| 25.09.2017 | Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics | - |
| 25.09.2017 | Fusion Pharmaceuticals Completes Series A Financing Totaling $46 Million | HAMILTON, Ontario–(BUSINESS WIRE)–September 25, 2017–
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second clo... |
| 23.02.2017 | FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation | - |
| 23.02.2017 | Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments | HAMILTON, Ontario–(BUSINESS WIRE)–February 23, 2017–
Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Ser... |
| 23.02.2017 | Fusion Pharmaceuticals Launches with USD$25M Series A Financing | Fusion Pharmaceuticals, a Hamilton, Ontario, Canada-based biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, closed a $25m Series A financing.
The round was led by founding venture investor J... |
| - | Fusion Pharmaceuticals Appoints New Chief Medical Officer | Hamilton, Ontario. 23 March 2020. Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers... |
| - | Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3. | Hamilton, Ontario and Boston, Massachusetts. July 28, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced tha... |
| - | Fusion Pharmaceuticals Announces Research Collaboration With Pepscan To Develop Peptide-Based Radiopharmaceuticals | HAMILTON, ON and BOSTON, Jan. 11, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the compa... |
| - | Fusion Pharmaceuticals Announces Research Collaboration With 48Hour Discovery To Develop Peptide-Based Radiopharmaceuticals | HAMILTON, Ontario and BOSTON, Jan. 11, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the ... |
| - | Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors | Boston, Massachusetts & Hamilton, Ontario. February 6, 2020. Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted alpha therapeutics, has announced the appointment of P... |
| - | Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing |
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investo... |
| - | Fusion Pharmaceuticals To Present At The 2022 Bloom Burton & Co. Healthcare Investor Conference | HAMILTON, ON and BOSTON, April 26, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the... |
| - | First Patient Dosed in Fusion Phase I trial. | Boston, Massachusetts & Hamilton, Ontario. February 19, 2019. Seroba portfolio company, Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (targeted alpha therapeutics) has announced the first patient was d... |
| - | Fusion Pharmaceuticals Presents Imaging Data From Cold Antibody Sub-Study In The Phase 1 Study Of FPI-1434 | – Study evaluates pre-administration of cold antibody prior to administration of imaging agent
– Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is pre-administered
– Data presented at the SNMMI... |
| - | Fusion Pharmaceuticals Announces Appointment of Steven Gannon to Board of Directors | Boston, MA & Hamilton, ON – March 4, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announ... |
| - | Fusion Pharmaceuticals Announces Investment From Canada Pension Plan Investment Board (CPPIB) | Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million fro... |
| - | Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434. | Hamilton, Ontario and Boston. June 14, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation o... |
| - | Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors | Hamilton, ON and Boston. April 1, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donal... |
| - | Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Cancer Trial | Hamilton, Ontario and Boston. 10 December 2020. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first ... |
| - | Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics | HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Se... |
| - | Fusion Pharmaceuticals And Niowave Announce Actinium-225 Collaboration And Supply Agreement | HAMILTON, ON and BOSTON and LANSING, Mich., June 10, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radio pharmaceuticals as precision medicines, and N... |
| - | Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results And Clinical Program Updates | – Company is advancing first targeted alpha therapy (TAT) candidate under collaboration with AstraZeneca
– Recently signed research collaborations support expansion of pipeline into peptide-based radiopharmaceuticals
– Company continues t... |
| - | Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development | Candidate Combines Fusion’s Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific Antibody
HAMILTON, Ontario and BOSTON, Jan. 10, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology co... |
| - | Fusion Raises $105m in Series B Financing. | Hamilton, Ontario and Dublin, Ireland. April 2nd 2019. Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced ... |
| - | Fusion Pharmaceuticals Announces Appointment Of John J. Crowley As Chief Financial Officer | BOSTON, MA and HAMILTON, ONTARIO, March 4, 2019 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the appointment of John J. Crowle... |
| - | Fusion Pharmaceuticals Announces Collaboration With AstraZeneca To Develop And Commercialize Next-Generation Radiopharmaceuticals And Combination Therapies. | Hamilton, Ontario and Boston, 2 November 2020. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration ... |
| - | Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Chief Medical Officer | Boston, MA & Hamilton, ON – March 23, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today annou... |
| - | Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-2059, An Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1 | HAMILTON, ON and BOSTON, June 23, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the ... |
| - | Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion’s Targeted Alpha Therapy (TAT) in Combination with Merck’s KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors... | Hamilton, Canada and Boston, USA. May 6, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has ente... |
| - | Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board | Hamilton, Ontario & Boston, Massachusetts. January 13, 2020. Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an invest... |
| - | Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results And Clinical Program Updates | Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022
Company continues to build a diversified pipeline of TATs and advance manufacturing and actinium supply chain capabilities
HAMILTON, ON & BOSTON, May 10, ... |
| - | Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments | HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing... |
